Table 1 Therapeutic perspectives of targeting CSCs in the tumor microenvironment
From: The role of tumor microenvironment on cancer stem cell fate in solid tumors
Drug | Cancer/Cell line | Description | Refs |
|---|---|---|---|
Cisplatin and vemurafenib | Melanoma | Enrichment of JARID1B slow-cycling subpopulation was formed Suspension of JARID1B+ subpopulation formation and making melanoma cells more vulnerable to chemotherapy agents | [302] |
Oligomycin, | PDAC cells with mutations in KRAS | Better elimination of CSCs rather than just using treatments specified for the oncogene | [303] |
5-fluorouracil and metformin | Colorectal cancer | Effectively reduced the population of CSCs by blocking the mitochondrial activity | [304] |
3-bromopyruvate and doxorubicin | Glioblastoma | Effective inhibition of tumor and elimination of CSCs | [305] |
VEGF monoclonal antibody and POL5551 | Glioblastoma | Enhanced survival via affecting the existing of CSCs | [307] |
anti-GPR77 antibody | Breast and lung cancer | Diminish tumor formation and sensitizing lung and breast cancer cells to chemotherapy | [310] |